Pernix Therapeutics (PTX) Misses Q1 EPS by 36c, Withdraws Guidance

Pernix Therapeutics (NASDAQ: PTX) reported Q1 EPS of ($0.42), $0.36 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $44.55 million.

• Pernix is temporarily withdrawing its prior 2016 financial guidance.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M